ERBB 2 receptor antagonists - Pipeline Insight, 2024

ERBB 2 receptor antagonists - Pipeline Insight, 2024

DelveInsight’s, “ERBB 2 receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in ERBB 2 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

ERBB 2 receptor antagonists Understanding

ERBB 2 receptor antagonists: Overview

The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. In humans, the family includes Her1 (EGFR, ErbB1), Her2 (Neu, ErbB2), Her3 (ErbB3), and Her4 (ErbB4). ERBB2, a known proto-oncogene, is located at the long arm of human chromosome 17 (17q12). All four contain an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.

""ERBB 2 receptor antagonists - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ERBB 2 receptor antagonists pipeline landscape is provided which includes the disease overview and ERBB 2 receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth ERBB 2 receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ERBB 2 receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence ERBB 2 receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve ERBB 2 receptor antagonists.

ERBB 2 receptor antagonists Emerging Drugs Chapters

This segment of the ERBB 2 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ERBB 2 receptor antagonists Emerging Drugs

• Pyrotinib: Jiangsu Hengrui Medicine

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Pyrotinib is a novel, irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed by Jiangsu Hengrui Medicine for the treatment of HER2-positive advanced solid tumors. Pyrotinib permanently binds to ATP binding sites in the intracellular kinase regions of HER1, HER2 and HER4, completely blocking the downstream pathway activated by homodimers or heterodimers of HER family on the tumor cell membrane. The drug is currently being evaluated in Phase III clinical trial to treat Non-small cell lung cancer.

• Afatinib: Boehringer Ingelheim

Afatinib is an antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. Afatinib is a potent and selective, irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signaling from all homo and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4. It is indicated for the treatment of Non-small cell lung cancer and being evaluated in Phase III stage of development for the treatment of Breast Cancer.

• OST-HER2: OS Therapies

OST-HER2 is targeting Osteosarcoma in children and young adults, and potentially other solid tumors. It is a Lm vector-based off-the-shelf Immunotherapy intended to prevent metastasis, delay recurrence, and increase overall survival. The OST-HER2 Lm vector platform technology has been administered to over 450 cancer patients in ongoing and completed clinical trials. AOST-2121 is a Phase IIB clinical trial intended to prevent metastasis and improve Overall Survival (OS) in Osteosarcoma. OST-HER2 has already received Fast-Track and Orphan Designations by the FDA and EMA - the company has filed for Rare Disease Designation (RDD). OST hopes to seek a Break-Through Designation (BTD) based on data from Phase IIb clinical trial.

Further product details are provided in the report……..

ERBB 2 receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different ERBB 2 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in ERBB 2 receptor antagonists

There are approx. 20+ key companies which are developing the therapies for ERBB 2 receptor antagonists. The companies which have their ERBB 2 receptor antagonists drug candidates in the most advanced stage, i.e. phase III include Jiangsu Hengrui Medicine.

● Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

ERBB 2 receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ERBB 2 receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ERBB 2 receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ERBB 2 receptor antagonists drugs.

ERBB 2 receptor antagonists Report Insights

• ERBB 2 receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

ERBB 2 receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing ERBB 2 receptor antagonists drugs?
• How many ERBB 2 receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ERBB 2 receptor antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ERBB 2 receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ERBB 2 receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?